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Endogenous Carbon Monoxide; We Don’t Know
Endogenous Carbon Monoxide (CO) is a gas involved 
in cell signalling events that are necessary for the 
regulation of biological systems. However, it leads to 
impaired efficiency of oxygen storage and transport 
by haemoglobin (Hb) through CO protein binding 
to haem. People breathing air without an environ-
mental CO source will still have measurable levels 
of circulating COHb due to both protein catabo-
lism and endogenous CO production. Endogenous 
CO is produced from the oxidative degradation of 
both proteins by the stress response enzyme haem 
oxygenase (HO). HO acts as a defence mechanism 
against oxidative stress and is induced by reactive 
oxygen species. CO production may be affected by 
various physiological factors, including disease [1]. 
In normal degradation of Hb, the porphyrin ring of 
the hem is broken with HO at the α-methine bridge. 
HO coexists with NADPH-flavoprotein reductase and 
biliverdin reductase on the endoplasmic reticulum, 
where it catabolizes haem, biliverdin, iron and CO 
in an O2 and NADPH-dependent manner. Biliverdin 
is then separated by biliverdin reductase, bilirubin, 
a potent endogenous antioxidant [2]. Increased levels 
of both after erythrocyte destruction, increased en-
dogenous CO production and increased COHb levels 
have been shown [3, 4]. When haemolysis and ab-
normal metabolism increase, the CO production rate 
in our body can increase significantly [4]. Both are the 
main site of catabolism and thus the main organ of 
CO production in the liver. Following the liver, spleen, 
brain and erythropoietic systems are organs and sys-
tems in which CO production occurs [5]. CO forma-
tion rates may be due to high levels of HO activity in 
these tissues [3, 4, 6]. Although CO was previously 
known only as a toxic gas with high binding proper-
ties to haemoglobin, it has now been shown to play 
an important role in many physiological and patho-
physiological processes in the cardiovascular, immune 
and neurological systems [7]. The physiological effect 
of CO occurs as nitric oxide increases the production 
of cyclic guanylate cyclase (cGMP) as well as increas-
es soluble cGMP [8]. CO, which has antiapoptotic 
and anti-inflammatory potential, has vasodilatation 
properties on the cardiovascular system [9]. Although 
the cytoprotective roles of CO, in vitro studies using 
CO-releasing molecules, and in vivo studies using 
high exogenous CO exposure have been investigated, 
the behaviour of CO under pathophysiological condi-
tions is still unknown [10]. While CO levels measured 
by carboxyhaemoglobin (COHb) have been shown to 
have high concentrations in smokers, endogenous 
CO concentration levels of those with various patho-
physiological conditions are uncertain [11]. There are 
several research articles related to endogenous COHb 
and diseases. One of them is the work of Kobayashi 
et al. Kobayashi et al. Investigated the relationship be-
tween endogenous COHb and ACS and divided them 
into four groups as non-smoker ACS and non-smoker 
ACS in 235 patients. As expected, COHb levels were 
higher in smokers. In this study, it was concluded that 
endogenous CO may be useful for evaluating the 
risk of cardiovascular stress [12]. One of the diseases 
investigated in relation to endogenous COHb and 
diseases is pulmonary embolism. Kakavas et al. Inves-
tigated COHb levels and prognosis in patients with 
pulmonary embolism. This study was retrospectively 
performed on 156 patients. In univariate logistic re-
gression analysis, COHb levels were associated with 
mortality and in multivariate analysis only COHb was 
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found to be an independent predictor of in-hospital 
mortality [13] as a result, endogenous COHb can still 
be studied in many diseases.
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